Harris Associates LP Has Boosted Bristol Myers Squibb Co (BMY) Position; Seaspine Holdings (SPNE) Shorts Decreased By 2.37%

April 25, 2018 - By wolcottdaily

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Seaspine Holdings Corporation (NASDAQ:SPNE) had a decrease of 2.37% in short interest. SPNE’s SI was 24,700 shares in April as released by FINRA. Its down 2.37% from 25,300 shares previously. With 39,300 avg volume, 1 days are for Seaspine Holdings Corporation (NASDAQ:SPNE)’s short sellers to cover SPNE’s short positions. The SI to Seaspine Holdings Corporation’s float is 0.24%. The stock decreased 1.07% or $0.12 during the last trading session, reaching $11.14. About 11,912 shares traded. SeaSpine Holdings Corporation (NASDAQ:SPNE) has risen 46.32% since April 25, 2017 and is uptrending. It has outperformed by 34.77% the S&P500.

Harris Associates LP increased Bristol Myers Squibb Co (BMY) stake by 25.49% reported in 2017Q4 SEC filing. Harris Associates LP acquired 99,905 shares as Bristol Myers Squibb Co (BMY)’s stock rose 2.38%. The Harris Associates LP holds 491,786 shares with $30.14M value, up from 391,881 last quarter. Bristol Myers Squibb Co now has $84.04 billion valuation. The stock decreased 0.35% or $0.18 during the last trading session, reaching $51.4. About 9.31 million shares traded or 2.54% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since April 25, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Among 3 analysts covering SeaSpine Hldgs (NASDAQ:SPNE), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SeaSpine Hldgs had 6 analyst reports since June 21, 2017 according to SRatingsIntel. The rating was maintained by Piper Jaffray on Friday, August 18 with “Buy”. The firm has “Buy” rating given on Tuesday, July 11 by BTIG Research. The stock of SeaSpine Holdings Corporation (NASDAQ:SPNE) has “Buy” rating given on Friday, March 2 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, September 28 by Piper Jaffray.

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and Internationally. The company has market cap of $161.95 million. The firm provides orthobiologics and spinal fusion hardware solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. It currently has negative earnings. The Company’s orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures.

Since December 12, 2017, it had 1 buy, and 1 insider sale for $85,985 activity. On Tuesday, December 12 the insider Lynch Thomas J. Jr. sold $335,172. Another trade for 4,000 shares valued at $249,187 was made by Samuels Theodore R. II on Friday, December 15.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 12 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 84 analyst reports since July 28, 2015 according to SRatingsIntel. As per Friday, August 19, the company rating was maintained by UBS. The firm earned “Neutral” rating on Tuesday, April 17 by Bank of America. Jefferies maintained the shares of BMY in report on Monday, February 26 with “Hold” rating. The firm earned “Equal-Weight” rating on Friday, September 9 by Barclays Capital. The rating was maintained by BMO Capital Markets with “Market Perform” on Wednesday, April 5. The rating was maintained by BMO Capital Markets on Friday, July 28 with “Underperform”. Leerink Swann maintained the shares of BMY in report on Monday, October 23 with “Outperform” rating. The rating was maintained by Jefferies with “Hold” on Thursday, November 16. The firm has “Buy” rating given on Wednesday, December 2 by Guggenheim. BMO Capital Markets maintained it with “Underperform” rating and $47 target in Wednesday, April 18 report.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 wolcottdaily

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: